AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NGVT

Li David H sold $765K of NGVT

Li David H (President & CEO) sold 10,092 shares of Ingevity Corp (NGVT) at an average of $75.77 ($74.71–$75.83, $0.76M total) across 3 trades over 2026-08-14 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Li David H
Published Aug 18, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NGVT
Neutral
medium confidence
Mentioned
$NGVT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGVTNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the disclosure does not provide new fundamentals or forward-looking guidance.

02

Market read

A scheduled insider sale of about $765K in NGVT shares was reported, with no other company-specific news included.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without changes to other insiders or new company disclosures, the trading edge is limited.

Relevance 4/10Novelty 4/10Timing: filed Aug 18, after-hours (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Ingevity (NGVT) by its President and CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$NGVTNeutralMedium confidence
Context

Ingevity CEO Li David H sold $764,673 of NGVT shares via a 10b5-1 plan across three trades from Aug 14 to Aug 18.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or operational change disclosed.

Market effects

Sector

Minimal, as this is company-specific insider selling with no sector-wide regulatory or demand signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with private information, but the pre-arranged nature reduces the signal strength.

Key entities

  • issuer
    Ingevity Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Li David H

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NGVT insider trading history →

Related articles

$NGVTMed

Ingevity (NGVT) Lifted EPS Guidance, Is The Stock Still Cheap?

Ingevity (NGVT) raised its full-year EPS guidance despite lower Q3 sales. The stock has fallen 15.34% in the past week but remains up 25.15% over one year. Analysts estimate fair value at $89, suggesting a 30% undervaluation, though its P/E ratio is higher than industry averages. The company plans $300M in share buybacks by 2027.

finance.yahoo.com
$NGVTHighAI 8/10

Ingevity Q3 Earnings Call Highlights

Ingevity (NGVT) reports Q3 earnings, highlighting growth in hybrid vehicle and filtration markets. CEO Dave Li notes benefits from the hybrid transition and new water treatment contracts. Pavement Technologies sales fell 24% due to divestiture and higher asphalt costs. Advanced Polymer Technologies sales rose 18%. The company narrowed its 2026 adjusted EBITDA outlook to $385M-$395M and expects $1.1B in sales. Ingevity repurchased $39M in shares during Q3.

finance.yahoo.com
$NGVTMed

Ingevity (NGVT) Q3 2026 Earnings Call Transcript

Ingevity (NGVT) reported Q3 2026 sales of $305M, down 8% YoY due to divestitures, but up 2% excluding them. Adjusted EBITDA was $108M, down 2%, with margins expanding to 35.4%. EPS rose 24% to $1.63. The company highlighted growth in filtration and water treatment, secured new contracts, and repurchased $39M in shares. Full-year adjusted EBITDA is expected to be $385M-$395M, with sales around $1.1B and EPS of $5.25-$5.45.

finance.yahoo.com
$NGVTMed

Ingevity reports third quarter 2026 financial results

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports third quarter 2026 financial results Third Quarter 2026 Results and Recent Highlights: • Net sales of $305.1 million decreased 8% from prior year; exclu

SEC EDGAR 8-K
$NGVTHigh

Ingevity reports third quarter 2026 financial results

Ingevity reported Q3 2026 net sales of $305.1M, down 8% YoY. Net income rose to $51.1M per diluted share. Adjusted EBITDA fell $108M but margin expanded to 35.4%. The company narrowed its full-year adjusted EBITDA outlook to $385M-$395M. CEO Dave Li cited strong Performance Materials but noted challenges in Pavement Technologies. Ingevity (NYSE: NGVT) plans to host an earnings call on November 5, 2026.

stocktitan.net